A new evaluation of the rearranged non-coding control region of JC virus in patients with colorectal cancer.

Autor: Haghi Navand A; Cancer, Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Jalilian S; Cancer, Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Ahmadi Angali K; Biostatistics and Epidemiology Department, Health School, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Karimi Babaahmadi M; Department of Medical Biotechnology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Talaiezadeh A; Cancer, Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran., Makvandi M; Cancer, Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. manoochehrmakvandi299@gmail.com.
Jazyk: angličtina
Zdroj: BMC cancer [BMC Cancer] 2024 Aug 12; Vol. 24 (1), pp. 1001. Date of Electronic Publication: 2024 Aug 12.
DOI: 10.1186/s12885-024-12684-x
Abstrakt: Background: Several studies have reported the presence of JC virus (JCV) in human tumors, The association of JCV and CRC remains controversial. This study aimed to evaluate the rearranged NCCR region of the detected JCV DNA in CRC patients' tissue samples.
Methods: In this case-control study, tumor tissues (n = 60), adjacent normal tissues (n = 60), and urine samples (n = 60) of the CRC patients were collected. The nested PCR was employed to detect the VP1 and NCCR regions of the JCV genome. The positive JCV PCR products were sequenced and a phylogenetic tree was constructed to determine the JCV genotypes. After extracting RNA and preparing cDNA, the expression of JCV LTAg was examined in 60 tumor tissues and 60 adjacent normal tissues. The analysis of JCV LTAg expression was performed using GraphPad Prism software version 8.
Results: The analysis reveals that JCV DNA was detected in 35/60 (58.3%) tumor tissues, while 36/60 (60.0%) of adjacent normal tissues (p = 0.85). JCV DNA was detected in 42/60 (70.0%) urine samples when compared to 35/60 (58.3%) tumor tissues of CRC patients and was not found significant (P = 0.25). The phylogenetic tree analysis showed the dominant JCV genotype 3, followed by genotype 2D was distributed in tumor tissue, normal tissue, and urine samples of the CRC patients. Analysis of randomly selected NCCR sequences from JCV regions in tumor tissue samples revealed the presence of rearranged NCCR blocks of different lengths.: 431 bp, 292 bp, 449 bp, and 356 bp. These rearranged NCCR blocks differ from the rearranged NCCR blocks described in PML-type Mad-1, Mad-4, Mad-7, and Mad-8 prototypes. The expression of JCV LTAg was significantly different in tumor tissue compared to normal tissue, with a p-value of less than 0.002.
Conclusion: A significant proportion of 35%> of the tumor tissue and urine samples of the CRC patients was found to be positive for JCV DNA (P = 0.25). The parallel analysis of tumor and urine samples for JCV DNA further supports the potential for non-invasive screening tools. This study provides new insights into Rearranged NCCR variant isolates from patients with CRC. The significant difference in JCV LTAg expression between tumor and normal tissue indicates a latent JCV status potentially leading to cancer development.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje